Dermpath Diagnostics

What Dermpath Diagnostics does

Dermpath Diagnostics is a US-based specialty dermatopathology laboratory brand operating as a wholly-owned subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), the diagnostic information services company headquartered in Secaucus, New Jersey. Quest acquired Dermpath in 2013, consolidating predecessor labs (Troy & Associates, founded 1981 in Brookfield, WI; Central Florida, founded 1985) into a unified dermatopathology network. The company provides microscopic examination of skin tissue, hair, and nails by a network of over 75 board-certified dermatopathologists, serving dermatologists and podiatrists across the United States through 14 laboratory locations in 10 states with nationwide specimen acceptance and a 24–48 hour turnaround time.

The company's technology stack centers on dermatopathology diagnostics with an expanding advanced genomic testing portfolio. Core offerings include histopathologic evaluation, special stains, immunoperoxidase stains, and direct/indirect immunofluorescence (housed in the dedicated Institute for Immunofluorescence). High-value genomic tests for melanoma include MelaNodal Predict (nodal staging prediction), MelanomaSEQ and MelanomaSEQPlus (comprehensive genomic profiling), and BRAF testing. Haystack MRD, developed through a technology partnership with Haystack Oncology, extends the portfolio into circulating tumor DNA (ctDNA) minimal residual disease testing for cancer patients. Quanum Lab Services Manager provides workflow management with integration across 600+ EMR systems, and the proprietary ASSIST system tracks specimens from receipt through result delivery.

Dermpath operates a B2B professional services revenue model billed primarily through health insurance reimbursement. It is in-network with Aetna, Horizon Blue Cross Blue Shield, UnitedHealthcare, traditional Medicare, and Medicaid, with self-pay pricing and financial assistance for uninsured patients. The customer base spans dermatology practices (primary), podiatric physicians (through the Institute for Podiatric Pathology), health plans, and patients. Go-to-market is direct enterprise field sales to dermatology and podiatry practices, supported by educational channels (Dermpath University, Dermpath Bowl at AAD annual meetings), MIPS/Quality Payment Program consulting, and the patient-facing Spot the Spot skin cancer awareness program.

Name

Dermpath Diagnostics

Legal name

Dermpath Diagnostics (operating as brand of Quest Diagnostics)

Website

https://dermpathdiagnostics.com

Company type

Private

Founded year

1981

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Dermpath Diagnostics, a wholly-owned subsidiary of Quest Diagnostics, is a US specialty dermatopathology laboratory brand operating 14 labs staffed by 75+ board-certified dermatopathologists, serving dermatologists, podiatrists, and patients with skin pathology diagnostics, advanced genomic testing, and MRD services.

Ownership category

akta.pro rank

Product category

Dermatopathology Diagnostic Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Dermatopathology (HLAKACAC)

akta.pro secondary industries

Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA), Anatomic Pathology & Histopathology (Trial Support) (HLAGAEAC), Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces (HLACAMAJ), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Dermatopathology services
• Skin pathology diagnostics
• Melanoma genomic testing
• Immunofluorescence dermatology
• Clinical laboratory testing

Headquarters

HQ city

Secaucus

HQ country

United States

HQ region

North America

Offices14 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Laboratory Diagnostic Services: Professional laboratory services for dermatopathology diagnosis billed to health insurance providers. Services include histopathologic evaluation, special stains, immunoperoxidase stains, immunofluorescence, and advanced genomic testing. Revenue generated through insurance claims submission.
2. Direct Patient Billing: Self-pay pricing for uninsured patients and those not using insurance coverage. Good Faith Estimates available upon request. Financial assistance programs offered.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Dermpath Diagnostics provides dermatopathology diagnostic laboratory services, including microscopic examination of skin tissue, hair, and nails by 75+ board-certified dermatopathologists, supported by special stains, immunoperoxidase staining, direct/indirect immunofluorescence, and advanced genomic profiling tests for melanoma (MelaNodal Predict, MelanomaSEQ, MelanomaSEQPlus, BRAF testing). The company also offers Haystack MRD ctDNA-based minimal residual disease testing for cancer patients, podiatric pathology through the Institute for Podiatric Pathology, and the Quanum physician portal integrating with 600+ EMR systems.

Product overview

Dermpath Diagnostics operates as a dermatopathology diagnostic services company offering a unified portfolio of specialized laboratory testing and professional services. The core offering is dermatopathology services with microscopic examination of skin tissue by board-certified dermatopathologists, supplemented by advanced genomic testing including MelaNodal Predict™, MelanomaSEQ®, and MelanomaSEQPlus® for melanoma patients. The company provides Haystack MRD™ for minimal residual disease testing in cancer patients. Supporting services include clinical testing (ANA Cascade, QuantiFERON®, T-SPOT®.*TB*, Prebiologics Panel), specialized divisions (Institute for Immunofluorescence, Institute for Podiatric Pathology), and educational platforms (Dermpath University®, Spot the Spot™). Integration with over 600 EMR systems and Quanum® Lab Services Manager workflow software enables streamlined operations for клиницистов.

Differentiator

Problem solved

Functional benefit

Brands

• Haystack MRD: Purpose-built, high-precision MRD (Minimal Residual Disease) testing for cancer patients, providing ultrasensitive circulating tumor DNA (ctDNA) testing.
• Dermpath University
• Dermpath Bowl
• Spot the Spot

Products and services

• Dermatopathology Diagnostic Services Core diagnostic service providing microscopic examination of skin tissue, hair, and nails by 75+ board-certified dermatopathologists for definitive diagnosis of skin disorders including melanoma, skin cancers, immunologic, infectious, and pediatric conditions. Serves referring dermatologists, dermatology practices, and podiatrists.
• Haystack MRD
• MelaNodal Predict
• MelanomaSEQ
• MelanomaSEQPlus
• BRAF Testing
• Direct and Indirect Immunofluorescence
• Institute for Podiatric Pathology Services
• Quanum Lab Services Manager
• TC/PC (Technical/Professional Component) Solution with MIPS Consulting
• HPV Typing
• Mycology and Bacteriology Analysis
• B Cell and T Cell Gene Rearrangement Studies
• Prebiologics Panel

Quantifiable outcome

• 24-48 hour turnaround time for dermatopathology results
• +1 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature7 records

Partnerships

Eight partnerships are on record, tiered core and supporting.

• Quest DiagnosticscoreOthersQuest Diagnostics is the parent company of Dermpath Diagnostics. Dermpath Diagnostics operates as a subsidiary brand under Quest Diagnostics, utilizing shared resources including the Quest Diagnostics comprehensive oncology testing portfolio, EMR integration platform (Quanum), and billing infrastructure through MyDocBill.com.
• Haystack OncologycoreTechnology or IntegrationTechnology partnership for Haystack MRD ctDNA testing based on more than 20 years of research developed by cancer genomics pioneers. Haystack MRD's purpose-built, high-precision science delivers novel insights for optimal treatment decision-making.
• Quest Diagnostics Nichols InstitutesupportingTechnology or IntegrationPartnership with Quest Diagnostics Nichols Institute for clinical and advanced testing menu including all-encompassing clinical testing, dermatologic disease state monitoring, and specialized testing.
• AetnacoreChannel Partner/ Reseller/ DistributorPreferred laboratory status with Aetna health insurance. Dermpath Diagnostics is in-network provider for Aetna members.
• Horizon Blue Cross Blue ShieldcoreChannel Partner/ Reseller/ DistributorPreferred laboratory status with Horizon health insurance. Dermpath Diagnostics is in-network provider for Horizon members.
• UnitedHealthcarecoreChannel Partner/ Reseller/ DistributorPreferred laboratory status with UnitedHealthcare. Dermpath Diagnostics is in-network provider for UnitedHealthcare members.
• Healthcare Quality Consulting (Quest HPQI)supportingStrategic or Co-development PartnerPartnership for MIPS consulting services helping practices navigate Quality Payment Program requirements. Quest Healthcare Performance and Quality Improvement Consulting Services provides MIPS assistance to Dermpath Diagnostics customers.
• EMR System VendorssupportingTechnology or IntegrationIntegration partnerships with 600+ EMR systems through Quanum Lab Services Manager for seamless electronic medical record connectivity.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Inform Diagnostics (now PathAI): Specialty anatomic pathology and dermatopathology provider now part of PathAI, offering both routine and AI-augmented pathology reads. Competes directly with Dermpath in dermatopathology and is actively pushing AI-driven disruption of the same workflow.
• Cockerell Dermatopathology: Independent dermatopathology specialty laboratory serving dermatologists across the US. Direct competitor in the same dermatopathology diagnostic niche with a comparable specialist-physician customer base and similar test menu.
• Caris Life Sciences: Oncology-focused molecular profiling and pathology lab offering comprehensive genomic profiling for solid tumors including melanoma. Overlaps with Dermpath's MelaNodal Predict, MelanomaSEQ, and BRAF testing menu in the melanoma and advanced oncology segments.
• Dermatopathology Laboratory of Central States: Independent dermatopathology reference lab serving dermatologists and podiatrists in the US. Directly comparable in scope, customer base, and service offering to Dermpath Diagnostics.
• Pathology Watch (by Sonic Healthcare): Dermatopathology and digital pathology lab serving dermatology groups nationwide, providing reads, digital slides, and integrated workflow. Directly competes with Dermpath for dermatology specimen volume and offers similar EMR-integrated services.

Emerging players

• Guardant Health: Liquid biopsy and MRD testing company with Guardant Reveal for MRD detection. Competitor in the same MRD space that Dermpath's Haystack MRD targets, particularly in oncology treatment decision-making.
• Natera: Specialized in ctDNA-based minimal residual disease (MRD) testing, including Signatera for solid tumor MRD. Directly comparable to Dermpath's Haystack MRD offering in the oncology MRD market that Dermpath/Quest is entering.

Broad incumbents

• ARUP Laboratories: National reference laboratory within the University of Utah system offering broad anatomic pathology, dermatopathology, and advanced molecular testing. Overlaps with Dermpath's test menu as a larger academic-affiliated reference competitor.
• BioReference Health (formerly BioReference Laboratories / OPKO Health subsidiary): National full-service clinical and anatomic pathology lab including dermatopathology. Competes for the same referring physician and dermatology group specimen volume across a broader test menu.
• Foundation Medicine: Comprehensive genomic profiling company (Roche subsidiary) for solid tumors including melanoma. Overlaps with Dermpath's MelanomaSEQ and BRAF testing in advanced oncology decision support.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/QuestDiagnosticsTV
• LinkedInlinkedin.com/company/dermpath-diagnostics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dermpath Diagnostics